New drug combo targets rare BRAF mutations in advanced cancers
NCT ID NCT03839342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests two oral drugs, binimetinib and encorafenib, in 26 adults with advanced solid tumors that have specific non-V600E BRAF mutations and no standard treatment options. The main goal is to see if the combination shrinks tumors. Researchers will also monitor side effects and how long patients live without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
binimetinib and encorafenib
What this could lead to
If successful, this could provide a new treatment option for people with advanced solid tumors that have certain rare BRAF mutations and have run out of standard therapies.
What could go wrong
This is a small, early-phase study with only 26 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G2M9, Canada